Sutro Biopharma's Trevor Hallam describes a future GMP manufacturing facility - - BioPharm International

ADVERTISEMENT

Sutro Biopharma's Trevor Hallam describes a future GMP manufacturing facility


blog comments powered by Disqus


In this second of three podcast interviews, Dr. Hallam, chief scientific officer at Sutro Biopharma, goes into some more detail about the protein expression system and describes a future GMP facility for the production therapeutic proteins and peptides. Batch sizes and yields are discussed, which for a cell-free system take on slightly different meaning; the cell extract used to produce the protein can be freeze-thawed and so effectively stockpiled. Once a sequence is known, the extract can be producing protein product 10 hours later, hence the systems potential robustness in a pandemic scenario. The new GMP facility, scheduled to open in 2012, will feature 200L fermenters for both extract and protein production at a scale that will take Sutro into Phase I and early Phase II studies. Dr. Hallam also delves into a product pipeline that is made up of Sutro's own candidates but also potential big pharma collaborative projects. The unique nature of the new process and intention for a GMP facility have led Sutro to initiate consultative discussions about regulatory requirements; early indications are positive, with quite some degree of excitement. Posted Nov. 2011.

Podcast 1 on the cell-free protein expression system

Related article on industrializing design, development, and manufacturing of therapeutic proteins

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here